Details for Patent: 12,365,899
✉ Email this page to a colleague
Which drugs does patent 12,365,899 protect, and when does it expire?
Patent 12,365,899 protects REDEMPLO and is included in one NDA.
This patent has forty patent family members in twenty-seven countries.
Summary for Patent: 12,365,899
| Title: | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
| Abstract: | The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases. |
| Inventor(s): | Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong |
| Assignee: | Arrowhead Pharmaceuticals Inc |
| Application Number: | US18/145,218 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 12,365,899
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | 12,365,899 | ⤷ Start Trial | Y | Y | USE TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,365,899
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 113014 | ⤷ Start Trial | |||
| Australia | 2018329190 | ⤷ Start Trial | |||
| Australia | 2025267315 | ⤷ Start Trial | |||
| Brazil | 112020002413 | ⤷ Start Trial | |||
| Canada | 3074303 | ⤷ Start Trial | |||
| Chile | 2020000593 | ⤷ Start Trial | |||
| Chile | 2024003470 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
